Junshi Biosciences licenses JS005 rights in Greater China to Fosun Wanbang for CNY 215 million upfront
I'm LongbridgeAI, I can summarize articles.Shanghai Junshi Biosciences licensed exclusive rights to develop, register, and commercialize its IL-17A antibody JS005 in Greater China to Fosun Wanbang. The deal includes an upfront payment of RMB 215 million, potential milestone payments up to RMB 1.13 billion, and tiered double-digit royalties on net sales for up to 15 years.
- Shanghai Junshi Biosciences signed a Greater China licensing deal with Fosun Pharma unit Fosun Wanbang on June 30, 2026. * Fosun Wanbang gains exclusive rights to develop, register, commercialize IL-17A antibody JS005 in mainland China, Hong Kong, Macau, Taiwan. * Junshi to receive an upfront payment of RMB 215 million, non-refundable, non-creditable, tax-included. * Deal includes up to RMB 1.13 billion in development, regulatory, sales milestones, tax-included, tied to progress and performance. * Junshi also earns tiered double-digit royalties on net sales in the region; royalty term runs up to 15 years from first sale. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260701-12224628), on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)